Michael G. Atieh

After starting his career with Ernst and Young where he became an Audit Manager, Mike spent the majority of his career in the biotechnology and pharmaceutical industries. Prior to his retirement in 2016, Mike was Executive Vice President, Chief Financial and Business Officer at Ophthotech, Inc. (Nasdaq: OPHT), a public biotechnology company. His previous experience included roles as Executive Chairman of Eyetech Inc., a private specialty pharmaceutical company; Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals (Nasdaq: OSIP), a public biotechnology company; and Senior Vice President and Chief Financial Officer of Dendrite International, Inc. (Nasdaq: DRTE), a pharmaceutical services company. In the 1990s, Mike held various senior corporate positions, including Treasurer at Merck & Co., Inc. (NYSE: MRK) and Vice President of US Human Health, a division of Merck.

Mike currently serves on the Board of Directors of Chubb Limited (NYSE: CB) where he is a member of the Risk and Finance Committee and previously served as the Chair of the Audit Committee from 2012 until May 2018. He also currently serves on the Board of Directors of Oyster Point Pharma (NASDAQ: OYST) where he is chairman of the Audit Committee. His previous public company board experience was with Theravance Biopharma (Nasdaq:TBPH) and OSI Pharmaceuticals, where he also served as Chair of the Audit Committee. Mike graduated from Upsala College with a Bachelor of Science in Accounting and Finance.